The Roles of Tissue Factor in Malignant Gliomas
This study has been completed.
Sponsor:
Ontario Clinical Oncology Group (OCOG)
Collaborator:
Ontario Cancer Research Network
Information provided by:
Ontario Clinical Oncology Group (OCOG)
ClinicalTrials.gov Identifier:
NCT00201903
First received: September 13, 2005
Last updated: May 18, 2007
Last verified: May 2007
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
To explore the relationship between tissue factor levels, tumour progression, activation of blood coagulation and venous thromboembolism with malignant glioma
| Condition |
|---|
|
Venous Thromboembolism Brain Tumors |
| Study Type: | Observational |
| Study Design: | Observational Model: Defined Population Observational Model: Natural History Time Perspective: Longitudinal Time Perspective: Prospective |
| Official Title: | The Roles of Tissue Factor in Malignant Gliomas |
Resource links provided by NLM:
Further study details as provided by Ontario Clinical Oncology Group (OCOG):
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- participation in PRODIGE
- adult patients
- newly diagnosed, biopsy-confirmed grade III/IV malignant gliomas
- undergone craniotomy or stereotactic biopsy > 2 days and < 4 weeks before
Exclusion Criteria:
- have known hereditary thrombophilia
- are receiving experimental antiangiogenic therapy
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00201903
Locations
| United States, Michigan | |
| Henry Ford Hospital | |
| Detroit, Michigan, United States, 48202 | |
| United States, Utah | |
| Huntsman Cancer Institute | |
| Salt Lake City, Utah, United States, 84112-5550 | |
| Canada, Alberta | |
| Cross Cancer Institute | |
| Edmonton, Alberta, Canada, T6G 1Z2 | |
| Canada, Manitoba | |
| CancerCare Manitoba | |
| Winnipeg, Manitoba, Canada, R3E 0V9 | |
| Canada, Ontario | |
| Princess Margaret Hospital | |
| Toronto, Ontario, Canada, M5G 2M9 | |
| Toronto-Sunnybrook Regional Cancer Centre | |
| Toronto, Ontario, Canada, M4N 3M5 | |
Sponsors and Collaborators
Ontario Clinical Oncology Group (OCOG)
Ontario Cancer Research Network
Investigators
| Study Chair: | Agnes Lee, MD | Hamilton Health Sciences and McMaster University |
| Principal Investigator: | William Geerts, MD | Sunnybrook Health Sciences Centre |
| Principal Investigator: | Mark Levine, MD | Ontario Clinical Oncology Group (OCOG) |
| Principal Investigator: | James Perry, MD | Toronto Sunnybrook Regional Cancer Centre |
| Principal Investigator: | Janusz Rak | Hamilton Health Sciences and McMaster University |
| Principal Investigator: | Jeffrey Weitz, MD | Hamilton Health Sciences and McMaster University |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00201903 History of Changes |
| Other Study ID Numbers: | OCOG-2003-TFsubstudy |
| Study First Received: | September 13, 2005 |
| Last Updated: | May 18, 2007 |
| Health Authority: | Canada: Health Canada |
Keywords provided by Ontario Clinical Oncology Group (OCOG):
|
venous thromboembolism brain tumours glioma tissue factor |
blood coagulation tumour progression low molecular weight heparin |
Additional relevant MeSH terms:
|
Brain Neoplasms Glioma Thromboembolism Venous Thromboembolism Venous Thrombosis Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site Neoplasms Brain Diseases Central Nervous System Diseases Nervous System Diseases Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal |
Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Embolism and Thrombosis Vascular Diseases Cardiovascular Diseases Thrombosis Heparin, Low-Molecular-Weight Thromboplastin Anticoagulants Hematologic Agents Therapeutic Uses Pharmacologic Actions Fibrinolytic Agents Fibrin Modulating Agents |
ClinicalTrials.gov processed this record on May 23, 2013